BChE-IN-4

BChE-IN-4 is a potent and cross the blood-brain barrier BChE inhibitor. BChE-IN-4 attenuates learning and memory deficits caused by cholinergic deficit in mouse model. BChE-IN-4 has the potential for the research of alzheimer’s disease[1].

Research Areas >> Neurological Disease

Signaling Pathways >> Neuronal Signaling >> AChE

BChE[1]

BChE-IN-4 (compound 1) (10, 20, 30 mg/kg) attenuates learning and memory deficits caused by cholinergic deficit in AD mouse model[1]. BChE-IN-4 (30 mg/kg) dose not induce adverse motor effects in vivo[1]. Animal Model: Adult male Albino Swiss CD-1 mice (Scopolamine-induced memory-impaired CD-1 mice)[1] Dosage: 10, 20, 30 mg/kg Administration: I.p. Result: Significantly prolonged the step-through latencies in memory impaired mice. Animal Model: 18-22 g, C57BL/6J mice[1] Dosage: 30 mg/kg Administration: I.p. Result: Did not enhance learning abilities and working memory in the acquisition phase or the short-term memory retrieval on day 5, but did significantly improve long-term memory retrieval, as observed on day 12 of the BM ( Barnes maze) task. Animal Model: Mice[1] Dosage: 30 mg/kg (suspended in 1% Tween 80) Administration: I.p Result: Neither altered the number of light-beam interruptions in the locomotor activity test nor induced any motor deficits at 6, 18 and 24 rpm in the rotarod test.

[1]. Meden A, et al. Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors. Eur J Med Chem. 2020 Dec 15;208:112766.